Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study
(2020)
Journal Article
Lawrence, H., Pick, H., Baskaran, V., Daniel, P., Rodrigo, C., Ashton, D., …Lim, W. S. (2020). Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLoS Medicine, 17(10), Article e1003326. https://doi.org/10.1371/journal.pmed.1003326
Background: Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available in the UK to adults aged 65 years or over and those in defined clinical risk groups. We evaluated the vaccine effectiveness (VE) of PPV23 against vac... Read More about Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study.